延长QT间期药物:慢性肾脏病中的使用 prevalence 与相关风险
本文为叙述性综述,旨在批判性评估延长QT间期药物在慢性肾脏病(CKD)中的病理生理相关性、使用 prevalence 及心血管后果。CKD患者因电解质紊乱、心肌重塑、自主神经功能障碍及药物暴露等多因素易出现QT间期延长,血液透析患者尤甚。基于美国肾脏数据系统的药物流行病学分析显示,延长QT间期药物与透析患者心脏性猝死风险升高相关。
要点
- CKD患者QT间期延长为多因素所致,包括电解质失衡、心肌重塑、自主神经功能障碍及延长QT间期药物暴露。
- 血液透析患者因透析中电解质和液体快速转移而尤其易发生QT间期延长。
- 基于美国肾脏数据系统的药物流行病学分析显示,延长QT间期药物与透析患者心脏性猝死风险升高相关。
核心结论
- 延长QT间期药物在CKD患者中广泛使用,且基于美国肾脏数据系统的药物流行病学分析显示其与透析患者心脏性猝死风险升高相关,需批判性评估其病理生理相关性、使用 prevalence 及心血管后果。
研究设计与样本
- 叙述性综述,旨在批判性评估延长QT间期药物在CKD中的病理生理相关性、使用 prevalence 及心血管后果。
主要发现
- CKD影响全球超过10%的成年人口,并与显著的心血管发病率和死亡率相关。
- 心脏性猝死(常由尖端扭转型室性心动过速等室性心律失常诱发)是CKD患者的主要死因之一。
- QT间期延长是CKD患者(无论是否透析)发生心律失常的重要危险因素,其机制涉及电解质失衡、心肌重塑、自主神经功能障碍及延长QT间期药物暴露。
- 血液透析患者因透析中电解质和液体快速转移而尤其易发生QT间期延长。
- 多种已知延长QT间期的药物(包括多种选择性5-羟色胺再摄取抑制剂、抗生素、止吐药和抗精神病药)常被处方给CKD患者,但关于其在该人群中安全性的数据很少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) affects >10% of the global adult population and is associated with substantial cardiovascular morbidity and mortality. Sudden cardiac death (often precipitated by ventricular arrhythmias like torsades de pointes) is a leading cause of death in patients with CKD. Prolongation of the QT interval (a marker of delayed ventricular repolarization) is a significant risk factor for arrhythmia in patients with CKD, whether they are on dialysis or not. QT prolongation in CKD is multifactorial and may result from electrolyte imbalances, myocardial remodelling, autonomic dysfunction and exposure to QT-prolonging drugs. Patients on haemodialysis are particularly vulnerable to QT prolongation due to rapid intradialytic electrolyte and fluid shifts. Many drugs known to prolong the QT interval (including various selective serotonin reuptake inhibitors, antibiotics, antiemetics and antipsychotics) are frequently prescribed to patients with CKD, even though there are few data on their safety in this population. The results of several well-designed pharmaco-epidemiological analyses (all based on data from the US Renal Data System) have shown associations between QT-prolonging drugs and an elevated risk of sudden cardiac death among patients on dialysis. These findings are concerning, given the widespread use of such drugs. The objective of this narrative review is to critically evaluate the pathophysiological relevance, prevalence and cardiovascular consequences of QT-prolonging drug use in the CKD setting.
引用
- Liabeuf S, Berdougo-Tritz J, Augey L, et al. QT-prolonging medications: prevalence of use and associated risks in CKD. Nephrol Dial Transplant. 2026. PMID: 40996451. doi:10.1093/ndt/gfaf196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。